Proxy Statement and Annual Report

The report describes Jazz Pharmaceuticals' strong 2022 execution, including total revenues of $3,659,374 thousand and continued growth across neuroscience and oncology products. It also documents the company's first materiality assessment to prioritize impactful ESG topics and explains that the board as a whole oversees ESG risks and opportunities. The report highlights a global workforce of approximately 2,800 people, including 54% female representation, and describes diversity, employee engagement, workplace safety and environmental management initiatives.